Adcytherix Launches Phase 1 Trial, Strengthens Leadership
Adcytherix has dosed the first patient in a Phase 1a/b study of ADCX-020, an exatecan‑derived topoisomerase I inhibitor antibody‑drug...
Pheast Therapeutics Advances New Cancer Drug to Phase 1b Trial
Pheast Therapeutics has dosed the first patient in the Phase 1b combination portion of its ongoing Phase 1 study...
Actinogen Commences Xanamia Alzheimer’s Open-Label Trial
No efficacy data yet. Actinogen has initiated the open-label extension of its XanaMIA pivotal program in Alzheimer’s disease, dosing...
The EMA’s Virtual Control Group Gambit Could Redraw the Map for Pivotal Trial Design
The EMA has opened consultation on a draft qualification opinion for virtual control groups — a methodology that, if...
The GLP-1 Mood Signal Is Real — But So Is the Psychiatric Worsening Risk
A pattern I’ve been tracking across my dual-diagnosis patient panel this year: the patients who come in asking about...
The Trial That Should Rewrite the Rare Disease Playbook — But Probably Won’t
AstraZeneca's Phase 3 benralizumab trial in hypereosinophilic syndrome just delivered one of the cleanest efficacy signals in rare disease...
Vor Bio Doses First Patient in Phase 3 Sjögren’s Trial
RemeGen’s prior Phase 3 study in China of telitacicept in primary Sjögren’s disease reported statistically significant and clinically meaningful...
ZUSDURI Delivers 72.2% Durable Response in enVision Trial
ZUSDURI delivered a 79.6% complete response at three months in the pivotal Phase 3 ENVISION study, with a Kaplan-Meier–estimated...
Quantum, Allucent Advance Phase 2 Multiple Sclerosis Trial
Quantum BioPharma has signed a binding letter of intent with Allucent to run a planned Phase 2 study of...
RenovoRx TIGeR-PaC Trial Surpasses 100 Patient Milestone
As of March 24, 2026, RenovoRx’s Phase III TIGeR-PaC trial in locally advanced pancreatic cancer has randomized 104 of...